Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Summit Therapeutics Inc. (SMMT)
|
Add to portfolio |
|
|
|
| Price: |
$2.80
| | Metrics |
| OS: |
697.7
|
M
| |
-500
|
% ROE
|
| Market cap: |
$1.95
|
B
| |
-33
|
% ROIC
|
|
Net cash:
|
$115
|
M
| |
$0.16
|
per share
|
|
EV:
|
$1.84
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($60.1)
|
M
| |
|
|
|
EBIT
|
($60.8)
|
M
| |
|
|
| EPS |
($1.70)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Jan-31-19 | Jan-31-17 | Jan-31-16 | Jan-31-15 | Jan-31-14 |
| Revenues | 0.7 | 1.8 | 0.9 | 57.1 | | -29.7 | 0.2 | 0.3 |
| Revenue growth | -61.0% | 110.3% | | | | -18627.4% | -38.1% | |
| Cost of goods sold | -116.0 | -150.9 | -112.0 | -119.5 | | 0.0 | 0.0 | 0.0 |
| Gross profit | 116.7 | 152.7 | 112.8 | 176.6 | | -29.7 | 0.2 | 0.3 |
| Gross margin | 16559.9% | 8441.6% | 13122.0% | 309.4% | | 100.0% | 100.0% | 100.0% |
| Research and development | 52.0 | 85.4 | 53.3 | 52.0 | | 10.4 | 0.1 | 0.1 |
| General and administrative | 26.7 | 23.6 | 19.2 | 17.0 | | 4.4 | 0.0 | 0.1 |
| EBITA | -62.7 | -85.2 | -51.1 | 11.8 | | -12.7 | 0.1 | 0.1 |
| EBITA margin | -8894.6% | -4708.1% | -5940.0% | 20.6% | | 42.8% | 36.6% | 34.5% |
| Amortization of intangibles | 0.9 | 1.0 | 1.3 | 1.1 | | | | |
| EBIT | -63.6 | -86.2 | -52.3 | 10.7 | | -12.7 | 0.1 | 0.1 |
| EBIT margin | -9024.3% | -4764.3% | -6085.3% | 18.7% | | 42.8% | 36.6% | 34.5% |
| Pre-tax income | -78.8 | -88.6 | -52.9 | 9.1 | | -12.7 | 0.1 | 0.1 |
| Income taxes | 0.0 | 0.0 | -0.2 | -1.8 | | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.4% | | | 0.0% | 0.0% | 0.0% |
| Net income | -78.8 | -88.6 | -52.7 | 10.9 | | 0.0 | 0.0 | 0.0 |
| Net margin | -11174.8% | -4897.8% | -6127.6% | 19.0% | | 0.0% | 0.0% | 0.0% |
| |
| Diluted EPS | ($0.41) | ($0.67) | ($0.76) | $0.63 | | | | |
| Shares outstanding (diluted) | 193.3 | 131.7 | 69.5 | 17.2 | | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|